Maria JoÃ£o Saraiva

List of Publications by Year
in descending order

222 papers	11,151 citations	22153 59 h-index	39675 94 g-index
225 all docs	225 docs citations	225 times ranked	7503 citing authors

#	Article	IF	Citations
1	The Expression of Chemokines Is Downregulated in a Pre-Clinical Model of TTR V30M Amyloidosis. Frontiers in Immunology, 2021, 12, 650269.	4.8	3
2	A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nature Communications, 2021, 12, 3142.	12.8	42
3	In Vitro and In Vivo Effects of SerpinA1 on the Modulation of Transthyretin Proteolysis. International Journal of Molecular Sciences, 2021, 22, 9488.	4.1	7
4	Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 97-102.	3.0	31
5	Neuronal megalin mediates synaptic plasticityâ€"a novel mechanism underlying intellectual disabilities in megalin gene pathologies. Brain Communications, 2020, 2, fcaa135.	3.3	10
6	SERPINA1 modulates expression of amyloidogenic transthyretin. Experimental Cell Research, 2020, 395, 112217.	2.6	7
7	Modulation of the Mechanisms Driving Transthyretin Amyloidosis. Frontiers in Molecular Neuroscience, 2020, 13, 592644.	2.9	24
8	Targeting transthyretin amyloidosis in the eye with next-generation stabilizers: AT40 displays potent TTR stabilization in the human vitreous. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 73-74.	3.0	2
9	Lead optimization of resilient next-generation transthyretin stabilizers for multiple target-product profiles: approaching the CNS. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 77-78.	3.0	1
10	Downregulated Cathepsin E expression in bone marrow-derived macrophages from the pre-clinical familial amyloid polyneuropathy model. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 63-64.	3.0	0
11	Transthyretin expression in the postischemic brain. PLoS ONE, 2019, 14, e0221555.	2.5	8
12	Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis. International Journal of Molecular Sciences, 2019, 20, 1287.	4.1	28
13	Anti-TTR Nanobodies Allow the Identification of TTR Neuritogenic Epitope Associated with TTR-Megalin Neurotrophic Activities. ACS Chemical Neuroscience, 2019, 10, 704-715.	3.5	5
14	Delivery of an antiâ€transthyretin Nanobody to the brain through intranasal administration reveals transthyretin expression and secretion by motor neurons. Journal of Neurochemistry, 2018, 145, 393-408.	3.9	22
15	Efficiency of siRNA for removal of transthyretin V30M in a TTR leptomeningeal animal model. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 38-39.	3.0	1
16	Doxycycline-tauroursodeoxycholic acid treatment: effects in the heart of a transthyretin V30M transgenic mouse model. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 80-80.	3.0	2
17	Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation. Scientific Reports, 2017, 7, 44709.	3.3	16
18	BDNF gene delivery mediated by neuron-targeted nanoparticles is neuroprotective in peripheral nerve injury. Biomaterials, 2017, 121, 83-96.	11.4	92

#	Article	IF	Citations
19	MMP-14 overexpression correlates with the neurodegenerative process in familial amyloidotic polyneuropathy. DMM Disease Models and Mechanisms, 2017, 10, 1253-1260.	2.4	18
20	Multimodal imaging Gd-nanoparticles functionalized with Pittsburgh compound B or a nanobody for amyloid plaques targeting. Nanomedicine, 2017, 12, 1675-1687.	3.3	29
21	Differential expression of Cathepsin E in transthyretin amyloidosis: from neuropathology to the immune system. Journal of Neuroinflammation, 2017, 14, 115.	7.2	16
22	Force spectroscopy reveals the presence of structurally modified dimers in transthyretin amyloid annular oligomers. Journal of Molecular Recognition, 2017, 30, e2587.	2.1	7
23	C1q ablation exacerbates amyloid deposition: A study in a transgenic mouse model of ATTRV30M amyloid neuropathy. PLoS ONE, 2017, 12, e0175767.	2.5	12
24	The importance of pre-clinical studies in animal models of TTR amyloidosis for the discovery of novel patient disease biomarkers. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 83-84.	3.0	0
25	Overexpression of Protocadherin-10 in Transthyretin-Related Familial Amyloidotic Polyneuropathy. American Journal of Pathology, 2016, 186, 1913-1924.	3.8	8
26	Curcumin: A multi-target disease-modifying agent for late-stage transthyretin amyloidosis. Scientific Reports, 2016, 6, 26623.	3.3	38
27	Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal animal model. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 249-253.	3.0	9
28	Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 109-118.	3.0	89
29	Tissue remodeling after interference RNA mediated knockdown of transthyretin in a familial amyloidotic polyneuropathy mouse model. Neurobiology of Aging, 2016, 47, 91-101.	3.1	5
30	Impairment of autophagy by TTR V30M aggregates: inÂvivo reversal by TUDCA and curcumin. Clinical Science, 2016, 130, 1665-1675.	4.3	11
31	Gd-nanoparticles functionalization with specific peptides for ÃŸ-amyloid plaques targeting. Journal of Nanobiotechnology, 2016, 14, 60.	9.1	55
32	Transthyretin participates in beta-amyloid transport from the brain to the liver- involvement of the low-density lipoprotein receptor-related protein 1?. Scientific Reports, 2016, 6, 20164.	3.3	71
33	Evidence for synergistic action of transthyretin and IGF-I over the IGF-I receptor. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 797-804.	3.8	7
34	A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition. European Journal of Medicinal Chemistry, 2016, 121, 823-840.	5.5	17
35	Homozygosity for the E526V Mutation in Fibrinogen A Alpha-Chain Amyloidosis: The First Report. Case Reports in Nephrology, 2015, 2015, 1-6.	0.4	4
36	Protective Role of Anakinra Against Transthyretin-Mediated Axonal Loss and Cell Death in a Mouse Model of Familial Amyloidotic Polyneuropathy. Journal of Neuropathology and Experimental Neurology, 2015, 74, 203-217.	1.7	10

#	Article	IF	Citations
37	Transthyretin Induces Insulin-like Growth Factor I Nuclear Translocation Regulating Its Levels in the Hippocampus. Molecular Neurobiology, 2015, 51, 1468-1479.	4.0	25
38	Polymer-doxycycline conjugates as fibril disrupters: An approach towards the treatment of a rare amyloidotic disease. Journal of Controlled Release, 2015, 198, 80-90.	9.9	27
39	Glial cells in familial amyloidotic polyneuropathy. Acta Neuropathologica Communications, 2014, 2, 177.	5.2	12
40	Transthyretin: a multifaceted protein. Biomolecular Concepts, 2014, 5, 45-54.	2.2	128
41	The inflammatory response to sciatic nerve injury in a familial amyloidotic polyneuropathy mouse model. Experimental Neurology, 2014, 257, 76-87.	4.1	24
42	Molecular Tweezers Targeting Transthyretin Amyloidosis. Neurotherapeutics, 2014, 11, 450-461.	4.4	41
43	Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 175-184.	3.0	38
44	Targeting a rare amyloidotic disease through rationally designed polymer conjugates. Journal of Controlled Release, 2014, 178, 95-100.	9.9	9
45	Transthyretin Stabilization by Iododiflunisal Promotes Amyloid-Î² Peptide Clearance, Decreases its Deposition, and Ameliorates Cognitive Deficits in an Alzheimer's Disease Mouse Model. Journal of Alzheimer's Disease, 2014, 39, 357-370.	2.6	45
46	Human TTRV30M localization within podocytes in a transgenic mouse model of transthyretin related amyloidosis: does the environment play a role?. Transgenic Research, 2013, 22, 101-116.	2.4	3
47	Fibroblasts endocytose and degrade transthyretin aggregates in transthyretin-related amyloidosis. Laboratory Investigation, 2013, 93, 911-920.	3.7	24
48	Hepatic production of transthyretin L12P leads to intracellular lysosomal aggregates in a new somatic transgenic mouse model. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1183-1193.	3.8	10
49	Hsf-1 affects podocyte markers NPHS1, NPHS2 and WT1 in a transgenic mouse model of TTRVal30Met-related amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 164-172.	3.0	2
50	Transthyretin regulates hippocampal 14â€3â€3Î¶ protein levels. FEBS Letters, 2013, 587, 1482-1488.	2.8	17
51	Dietary curcumin counteracts extracellular transthyretin deposition: Insights on the mechanism of amyloid inhibition. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 39-45.	3.8	43
52	Presence of Nâ€glycosylated transthyretin in plasma of V30M carriers in familial amyloidotic polyneuropathy: an escape from <scp>ERAD</scp>. Journal of Cellular and Molecular Medicine, 2013, 17, 429-435.	3.6	15
53	Transthyretin Deposition in Familial Amyloidotic Polyneuropathy. Current Medicinal Chemistry, 2012, 19, 2304-2311.	2.4	52
54	Transthyretin Decrease in Plasma of MCI and AD Patients: Investigation of Mechanisms for Disease Modulation. Current Alzheimer Research, 2012, 9, 881-889.	1.4	48

#	Article	IF	Citations
55	Transthyretin is a metallopeptidase with an inducible active site. Biochemical Journal, 2012, 443, 769-778.	3.7	40
56	Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 167-170.	3.0	229
57	Clearance of extracellular misfolded proteins in systemic amyloidosis: Experience with transthyretin. FEBS Letters, 2012, 586, 2891-2896.	2.8	25
58	Natural polyphenols as modulators of TTR amyloidogenesis: in vitro and in vivo evidences towards therapy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 39-42.	3.0	26
59	The heat shock response in FAP: the role of the extracellular chaperone clusterin. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 3-4.	3.0	6
60	Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 34-36.	3.0	184
61	Distinct Annular Oligomers Captured along the Assembly and Disassembly Pathways of Transthyretin Amyloid Protofibrils. PLoS ONE, 2012, 7, e44992.	2.5	42
62	A novel nanoparticle delivery system for in vivo targeting of the sciatic nerve: impact on regeneration. Nanomedicine, 2012, 7, 1167-1180.	3.3	16
63	Transthyretin: roles in the nervous system beyond thyroxine and retinol transport. Expert Review of Endocrinology and Metabolism, 2012, 7, 181-189.	2.4	11
64	Epigallocatechin-3-Gallate as a Potential Therapeutic Drug for TTR-Related Amyloidosis: â€œIn Vivoâ€• Evidence from FAP Mice Models. PLoS ONE, 2012, 7, e29933.	2.5	94
65	Stability of the Transthyretin Molecule as a Key Factor in the Interaction with A-Beta Peptide - Relevance in Alzheimer's Disease. PLoS ONE, 2012, 7, e45368.	2.5	39
66	Transthyretin Aggregation and Toxicity. , 2012, , 407-432.		0
67	Successful Heart and Liver Transplantation in a Swiss Patient With Glu89Lys Transthyretin Amyloidosis. Transplantation, 2011, 91, e40-e42.	1.0	4
68	Clusterin Overexpression and Its Possible Protective Role in Transthyretin Deposition in Familial Amyloidotic Polyneuropathy. Journal of Neuropathology and Experimental Neurology, 2011, 70, 1097-1106.	1.7	20
69	Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Letters, 2011, 585, 2424-2430.	2.8	133
70	Progesterone Enhances Transthyretin Expression in the Rat Choroid Plexus In Vitro and In Vivo via Progesterone Receptor. Journal of Molecular Neuroscience, 2011, 44, 152-158.	2.3	19
71	Structural insights into a zinc-dependent pathway leading to Leu55Pro transthyretin amyloid fibrils. Acta Crystallographica Section D: Biological Crystallography, 2011, 67, 1035-1044.	2.5	15
72	Structure and assemblyâ€“disassembly properties of wildâ€type transthyretin amyloid protofibrils observed with atomic force microscopy. Journal of Molecular Recognition, 2011, 24, 467-476.	2.1	22

#	Article	IF	Citations
73	Gender-Dependent Transthyretin Modulation of Brain Amyloid-Î² Levels: Evidence from a Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 429-439.	2.6	40
74	Solution Structure of the Soluble Receptor for Advanced Glycation End Products (sRAGE). Journal of Biological Chemistry, 2011, 286, 37525-37534.	3.4	32
75	Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 5584-5589.	7.1	76
76	Controlling Amyloidâ€Î² Peptide(1â€“42) Oligomerization and Toxicity by Fluorinated Nanoparticles. ChemBioChem, 2010, 11, 1905-1913.	2.6	42
77	Randomization of Amyloidâ€Î²â€Peptide(1â€42) Conformation by Sulfonated and Sulfated Nanoparticles Reduces Aggregation and Cytotoxicity. Macromolecular Bioscience, 2010, 10, 1152-1163.	4.1	35
78	CSF transthyretin neuroprotection in a mouse model of brain ischemia. Journal of Neurochemistry, 2010, 115, 1434-1444.	3.9	73
79	Human metallothioneins 2 and 3 differentially affect amyloidâ€beta binding by transthyretin. FEBS Journal, 2010, 277, 3427-3436.	4.7	25
80	Î±Bâ€crystallin (HspB5) in familial amyloidotic polyneuropathy. International Journal of Experimental Pathology, 2010, 91, 515-521.	1.3	13
81	Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2010, 17, 101-104.	3.0	302
82	Carvedilol treatment reduces transthyretin deposition in a familial amyloidotic polyneuropathy mouse model. Pharmacological Research, 2010, 62, 514-522.	7.1	34
83	Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. Journal of Translational Medicine, 2010, 8, 74.	4.4	149
84	The heat shock response modulates transthyretin deposition in the peripheral and autonomic nervous systems. Neurobiology of Aging, 2010, 31, 280-289.	3.1	59
85	Iodine Atoms: A New Molecular Feature for the Design of Potent Transthyretin Fibrillogenesis Inhibitors. PLoS ONE, 2009, 4, e4124.	2.5	51
86	Transthyretin Internalization by Sensory Neurons Is Megalin Mediated and Necessary for Its Neuritogenic Activity. Journal of Neuroscience, 2009, 29, 3220-3232.	3.6	118
87	Binding of epigallocatechinâ€3â€gallate to transthyretin modulates its amyloidogenicity. FEBS Letters, 2009, 583, 3569-3576.	2.8	122
88	17Î²-Estradiol Induces Transthyretin Expression in Murine Choroid Plexus via an Oestrogen Receptor Dependent Pathway. Cellular and Molecular Neurobiology, 2009, 29, 475-483.	3.3	41
89	Isatin derivatives, a novel class of transthyretin fibrillogenesis inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5270-5273.	2.2	44
90	Design and biological activity of Î²-sheet breaker peptide conjugates. Biochemical and Biophysical Research Communications, 2009, 380, 397-401.	2.1	45

#	Article	IF	Citations
91	Molecular Pathogenesis Associated with Familial Amyloidotic Polyneuropathy. , 2009, , 191-200.		0
92	Transthyretin is up-regulated by sex hormones in mice liver. Molecular and Cellular Biochemistry, 2008, 317, 137-142.	3.1	57
93	Iodination of salicylic acid improves its binding to transthyretin. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2008, 1784, 512-517.	2.3	16
94	Transthyretin binding to Aâ€Beta peptide â€“ Impact on Aâ€Beta fibrillogenesis and toxicity. FEBS Letters, 2008, 582, 936-942.	2.8	125
95	Amyloidogenic properties of transthyretinâ€like protein (TLP) from Escherichia coli. FEBS Letters, 2008, 582, 2893-2898.	2.8	5
96	5Î±-dihydrotestosterone up-regulates transthyretin levels in mice and rat choroid plexus via an androgen receptor independent pathway. Brain Research, 2008, 1229, 18-26.	2.2	28
97	Transthyretin Interacts with Metallothionein 2. Biochemistry, 2008, 47, 2244-2251.	2.5	34
98	Transthyretin is not expressed by dorsal root ganglia cells. Experimental Neurology, 2008, 214, 362-365.	4.1	15
99	Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 517-522.	3.8	57
100	Activation of the Heat Shock Response in Familial Amyloidotic Polyneuropathy. Journal of Neuropathology and Experimental Neurology, 2008, 67, 449-455.	1.7	13
101	Extracellular Matrix Markers for Disease Progression and Follow-Up of Therapies in Familial Amyloid Polyneuropathy V30M TTR-Related. Disease Markers, 2008, 25, 37-47.	1.3	21
102	Transthyretin Protects against A-Beta Peptide Toxicity by Proteolytic Cleavage of the Peptide: A Mechanism Sensitive to the Kunitz Protease Inhibitor. PLoS ONE, 2008, 3, e2899.	2.5	95
103	Accelerated AÂ Deposition in APPswe/PS1ÂE9 Mice with Hemizygous Deletions of TTR (Transthyretin). Journal of Neuroscience, 2007, 27, 7006-7010.	3.6	124
104	Familial amyloid polyneuropathy associated with TTRSer50Arg mutation in two Iberian families presenting a novel single base change in the mutant gene. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 147-152.	3.0	5
105	ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity. Journal of Lipid Research, 2007, 48, 2385-2395.	4.2	64
106	Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design. Biochemical Journal, 2007, 408, 131-138.	3.7	30
107	Transthyretin and Alzheimer's disease: Where in the brain?. Neurobiology of Aging, 2007, 28, 713-718.	3.1	97
108	A primer of amyloid nomenclature. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 179-183.	3.0	306

#	Article	IF	Citations
109	Biomarkers in the Assessment of Therapies for Familial Amyloidotic Polyneuropathy. Molecular Medicine, 2007, 13, 584-591.	4.4	24
110	Genetic microheterogeneity of human transthyretin detected by IEF. Electrophoresis, 2007, 28, 2053-2064.	2.4	37
111	Structural basis for the protective role of sulfite against transthyretin amyloid formation. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2007, 1774, 59-64.	2.3	24
112	Impairment of the ubiquitinâ€“proteasome system associated with extracellular transthyretin aggregates in familial amyloidotic polyneuropathy. Journal of Pathology, 2007, 213, 200-209.	4.5	16
113	Transthyretin enhances nerve regeneration. Journal of Neurochemistry, 2007, 103, 831-839.	3.9	118
114	Transthyretin: No association between serum levels or gene variants and schizophrenia. Journal of Psychiatric Research, 2007, 41, 667-672.	3.1	8
115	Inflammation and Apoptotic Pathways in the Peripheral Nervous System Related to Protein Misfolding. , 2007, , 271-280.		0
116	In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced glycation end products (RAGE). FEBS Letters, 2006, 580, 3451-3456.	2.8	24
117	The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin. Acta Crystallographica Section D: Biological Crystallography, 2006, 62, 512-519.	2.5	14
118	Activation of ERK1/2 MAP kinases in Familial Amyloidotic Polyneuropathy. Journal of Neurochemistry, 2006, 97, 151-161.	3.9	52
119	Immunization in familial amyloidotic polyneuropathy: counteracting deposition by immunization with a Y78F TTR mutant. Laboratory Investigation, 2006, 86, 23-31.	3.7	43
120	Endoplasmic Reticulum Stress Associated with Extracellular Aggregates. Journal of Biological Chemistry, 2006, 281, 21998-22003.	3.4	75
121	Transthyretin knockouts are a new mouse model for increased neuropeptide Y. FASEB Journal, 2006, 20, 166-168.	0.5	62
122	Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB Journal, 2006, 20, 234-239.	0.5	136
123	Human transthyretin in complex with iododiflunisal: structural features associated with a potent amyloid inhibitor. Biochemical Journal, 2005, 388, 615-621.	3.7	53
124	The binding of xanthone derivatives to transthyretin. Biochemical Pharmacology, 2005, 70, 1861-1869.	4.4	30
125	X-ray crystallographic studies of two transthyretin variants: further insights into amyloidogenesis. Acta Crystallographica Section D: Biological Crystallography, 2005, 61, 333-339.	2.5	12
126	Transthyretin is not necessary for thyroid hormone metabolism in conditions of increased hormone demand. Journal of Endocrinology, 2005, 187, 257-266.	2.6	21

#	Article	IF	Citations
127	Small Transthyretin (TTR) Ligands as Possible Therapeutic Agents in TTR Amyloidoses. CNS and Neurological Disorders, 2005, 4, 587-596.	4.3	54
128	Upâ€regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinaseâ€associated lipocalin and matrix metalloproteinaseâ€9 in familial amyloid polyneuropathy. FASEB Journal, 2005, 19, 124-126.	0.5	67
129	Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease. Human Molecular Genetics, 2005, 14, 543-553.	2.9	108
130	Amyloid: Toward terminology clarification Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 1-4.	3.0	314
131	Genetic epidemiology of familial amyloid polyneuropathy in the Balearic Islands (Spain). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 54-61.	3.0	31
132	Kinetic Assay for High-Throughput Screening of In Vitro Transthyretin Amyloid Fibrillogenesis Inhibitors. ACS Combinatorial Science, 2005, 7, 246-252.	3.3	39
133	Transthyretin, a New Cryptic Protease. Journal of Biological Chemistry, 2004, 279, 21431-21438.	3.4	76
134	The Crystal Structure of Transthyretin in Complex with Diethylstilbestrol. Journal of Biological Chemistry, 2004, 279, 53483-53490.	3.4	45
135	Haplotypes and DNA sequence variation within and surrounding the transthyretin gene: genotypeâ€“phenotype correlations in familial amyloid polyneuropathy (V30M) in Portugal and Sweden. European Journal of Human Genetics, 2004, 12, 225-237.	2.8	51
136	Deposition and passage of transthyretin through the blood-nerve barrier in recipients of familial amyloid polyneuropathy livers. Laboratory Investigation, 2004, 84, 865-873.	3.7	64
137	Familial Amyloidotic Polyneuropathy: Protein Aggregation in the Peripheral Nervous System. Journal of Molecular Neuroscience, 2004, 23, 035-040.	2.3	14
138	Sulfite and base for the treatment of familial amyloidotic polyneuropathy: two additive approaches to stabilize the conformation of human amyloidogenic transthyretin. Neurogenetics, 2004, 5, 61-67.	1.4	26
139	Transthyretin is involved in depression-like behaviour and exploratory activity. Journal of Neurochemistry, 2004, 88, 1052-1058.	3.9	111
140	Mutant fibrinogen A-Î±-chain associated with hereditary renal amyloidosis and peripheral neuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2004, 11, 200-207.	3.0	20
141	Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochemical Journal, 2004, 381, 351-356.	3.7	88
142	Enlarged ventricles, astrogliosis and neurodegeneration in heat shock factor 1 null mouse brain. Neuroscience, 2004, 126, 657-663.	2.3	61
143	Human transthyretin intronic open reading frames are not independently expressed in vivo or part of functional transcripts. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2003, 1626, 65-74.	2.4	5
144	Gelsolin-related familial amyloidosis, Finnish type, in a Portuguese family: Clinical and neurophysiological studies. Muscle and Nerve, 2003, 28, 715-721.	2.2	32

#	Article	IF	Citations
145	Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling. Progress in Neurobiology, 2003, 71, 385-400.	5.7	116
146	X-ray Absorption Spectroscopy Reveals a Substantial Increase of Sulfur Oxidation in Transthyretin (TTR) upon Fibrillization. Journal of Biological Chemistry, 2003, 278, 11654-11660.	3.4	18
147	4 â€²â€iodoâ€4â€²â€Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB Journal, 2003, 17, 803-809.	0.5	117
148	First Spanish family with familial amyloidotic polyneuropathy associated to TTR Thr49Ile mutation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 34-35.	3.0	6
149	Cellular consequences of transthyretin deposition. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10 Suppl 1, 13-6.	3.0	8
150	Sporadic Cases of Hereditary Systemic Amyloidosis. New England Journal of Medicine, 2002, 346, 1818-1819.	27.0	39
151	Amyloid Fibril Protein Nomenclature - 2002. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 197-200.	3.0	176
152	Evidence for Early Cytotoxic Aggregates in Transgenic Mice for Human Transthyretin Leu55Pro. American Journal of Pathology, 2002, 161, 1935-1948.	3.8	98
153	Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies. Expert Reviews in Molecular Medicine, 2002, 4, 1-11.	3.9	44
154	Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils 1 1Edited by M. Moody. Journal of Molecular Biology, 2002, 317, 683-695.	4.2	112
155	Thyroid hormone distribution in the mouse brain: the role of transthyretin. Neuroscience, 2002, 113, 837-847.	2.3	51
156	Sulphur K-edge XANES Spectroscopy of Transthyretin Amyloid Fibres. Spectroscopy, 2002, 16, 281-283.	0.8	0
157	Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution. Journal of Molecular Biology, 2001, 306, 733-744.	4.2	85
158	Deposition of Transthyretin in Early Stages of Familial Amyloidotic Polyneuropathy. American Journal of Pathology, 2001, 159, 1993-2000.	3.8	303
159	Transthyretin amyloidosis: a tale of weak interactions. FEBS Letters, 2001, 498, 201-203.	2.8	82
160	Tetramer Dissociation and Monomer Partial Unfolding Precedes Protofibril Formation in Amyloidogenic Transthyretin Variants. Journal of Biological Chemistry, 2001, 276, 27207-27213.	3.4	274
161	Familial Amyloid Polyneuropathy: Receptor for Advanced Glycation End Products-Dependent Triggering of Neuronal Inflammatory and Apoptotic Pathways. Journal of Neuroscience, 2001, 21, 7576-7586.	3.6	190
162	Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy. Journal of Molecular Medicine, 2001, 78, 703-707.	3.9	18

#	Article	IF	Citations
163	Preimplantation genetic diagnosis for familial amyloidotic polyneuropathy (FAP). Prenatal Diagnosis, 2001, 21, 1093-1099.	2.3	28
164	Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Human Mutation, 2001, 17, 493-503.	2.5	200
165	Internalization of Transthyretin. Journal of Biological Chemistry, 2001, 276, 14420-14425.	3.4	61
166	Two Spanish sibs with familial amyloidotic polyneuropathy homozygous for the V30M-TTR gene. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2001, 8, 121-123.	3.0	11
167	Designing transthyretin mutants affecting tetrameric structure: implications in amyloidogenicity. Biochemical Journal, 2000, 348, 167.	3.7	14
168	The molecular interaction of 4â€²-iodo-4â€²-deoxydoxorubicin with Leu-55Pro transthyretin â€˜amyloid-likeâ€™ oligomer leading to disaggregation. Biochemical Journal, 2000, 351, 273.	3.7	24
169	The molecular interaction of 4â€²-iodo-4â€²-deoxydoxorubicin with Leu-55Pro transthyretin â€˜amyloid-likeâ€™ oligomer leading to disaggregation. Biochemical Journal, 2000, 351, 273-279.	3.7	42
170	New transthyretin mutation V28M in a Portuguese kindred with amyloid polyneuropathy. Muscle and Nerve, 2000, 23, 1016-1021.	2.2	18
171	Aprotinin binding to amyloid fibrils. FEBS Journal, 2000, 267, 2307-2311.	0.2	20
172	Familial amyloid polyneuropathy in a Spanish family with a transthyretin deletion (Î”Val 122) presenting with carpal tunnel syndrome. Clinical Genetics, 2000, 58, 411-412.	2.0	5
173	Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin. Biophysical Chemistry, 2000, 88, 61-67.	2.8	53
174	Interaction of the Receptor for Advanced Glycation End Products (RAGE) with Transthyretin Triggers Nuclear Transcription Factor kB (NF-kB) Activation. Laboratory Investigation, 2000, 80, 1101-1110.	3.7	156
175	Evidence for the Role of Megalin in Renal Uptake of Transthyretin. Journal of Biological Chemistry, 2000, 275, 38176-38181.	3.4	109
176	Vitreous amyloidosis after liver transplantation in patients with familial amyloid polyneuropathy: Ocular synthesis of mutant transthyretin. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2000, 7, 266-269.	3.0	46
177	Comparative Studies of Two Transthyretin Variants with Protective Effects on Familial Amyloidotic Polyneuropathy: TTR R104H and TTR T119M. Biochemical and Biophysical Research Communications, 2000, 270, 1024-1028.	2.1	61
178	Search for intermediate structures in transthyretin fibrillogenesis: soluble tetrameric Tyr78Phe TTR expresses a specific epitope present only in amyloid fibrils. Journal of Molecular Biology, 2000, 304, 461-470.	4.2	45
179	Review: TTR Amyloidosisâ€”Structural Features Leading to Protein Aggregation and Their Implications on Therapeutic Strategies. Journal of Structural Biology, 2000, 130, 290-299.	2.8	78
180	Apolipoprotein AI and Transthyretin as Components of Amyloid Fibrils in a Kindred with apoAI Leu178His Amyloidosis. American Journal of Pathology, 2000, 156, 1911-1917.	3.8	94

#	Article	IF	Citations
181	4â€²-Iodo-4â€²-Deoxydoxorubicin Disrupts the Fibrillar Structure of Transthyretin Amyloid. American Journal of Pathology, 2000, 156, 1919-1925.	3.8	55
182	Transthyretin in high density lipoproteins: association with apolipoprotein A-I. Journal of Lipid Research, 2000, 41, 58-65.	4.2	75
183	Transthyretin Regulates Thyroid Hormone Levels in the Choroid Plexus, But Not in the Brain Parenchyma: Study in a Transthyretin-Null Mouse Model. Endocrinology, 2000, 141, 3267-3272.	2.8	24
184	Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 3108-3113.	7.1	65
185	The Tetrameric Protein Transthyretin Dissociates to a Non-native Monomer in Solution. Journal of Biological Chemistry, 1999, 274, 32943-32949.	3.4	160
186	Genetic anticipation in Portuguese kindreds with familial amyloidotic polyneuropathy is unlikely to be caused by triplet repeat expansions. Human Genetics, 1999, 104, 480-485.	3.8	31
187	A new transthyretin variant-ATTR Arg l04 Cys. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1999, 6, 149-151.	3.0	2
188	Unusual Self-Association Properties of Transthyretin Y114C Related to Familial Amyloidotic Polyneuropathy: Effects on Detection and Quantification. Biochemical and Biophysical Research Communications, 1999, 261, 264-269.	2.1	14
189	A Novel Compound Heterozygote (FAP ATTR Arg104His/ATTR Val30Met) with High Serum Transthyretin (TTR) and Retinol Binding Protein (RBP) Levels. Biochemical and Biophysical Research Communications, 1999, 264, 365-370.	2.1	55
190	Ultrastructure of Familial Amyloid Polyneuropathy Amyloid Fibrils: Examination with High-Resolution Electron Microscopy. Journal of Structural Biology, 1998, 124, 1-12.	2.8	67
191	The Crystal Structure of Amyloidogenic Leu55â†' Pro Transthyretin Variant Reveals a Possible Pathway for Transthyretin Polymerization into Amyloid Fibrils. Journal of Biological Chemistry, 1998, 273, 24715-24722.	3.4	116
192	Analysis of x-ray diffraction patterns from amyloid of biopsied vitreous humor and kidney of transthyretin (TTR) Met30 familial amyloidotic polyneuropathy (FAP) patients: axially arrayed TTR monomers constitute the protofilament. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1998, 5, 163-174.	3.0	44
193	Third International Symposium on familial amyloidotic polyneuropathy and other TTR related disorders Lisbon, Portugal, October 27â€“28, 1995. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1997, 4, 212-213.	3.0	0
194	The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. FEBS Letters, 1997, 418, 297-300.	2.8	94
195	Comparative Stability and Clearance of [Met30]Transthyretin and [Met119]Transthyretin. FEBS Journal, 1997, 249, 662-668.	0.2	68
196	LETTERS TO THE EDITOR. Toxicology and Applied Pharmacology, 1997, 144, 204.	2.8	1
197	Thyroxine binding to transthyretin Met 119. Endocrine, 1997, 6, 309-315.	2.3	90
198	Screening and biochemical characterization of transthyretin variants in the Portuguese population. Human Mutation, 1997, 9, 226-233.	2.5	41

#	Article	IF	Citations
199	Transthyretin gene in Alzheimer's disease patients. Neuroscience Letters, 1996, 204, 212-214.	2.1	29
200	â€˜In vitroâ€™ amyloid fibril formation from transthyretin: the influence of ions and the amyloidogenicity of TTR variants. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1996, 1316, 35-42.	3.8	39
201	CIBA Foundation Symposium No. 199 The Nature and Origin of Amyloid Fibrils. Lisbon, Portugal, October 23-26, 1995. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1996, 3, 209-211.	3.0	0
202	Structure of the Val122Ile Variant Transthyretin â€“ a Cardiomyopathic Mutant. Acta Crystallographica Section D: Biological Crystallography, 1996, 52, 966-972.	2.5	31
203	Thyroxine binding to transthyretin (TTR) variantsâ€”two variants (TTR Pro 55 and TTR Met 111) with a particularly low binding affinity. European Journal of Endocrinology, 1996, 135, 226-230.	3.7	17
204	Transthyretin mutations in health and disease. Human Mutation, 1995, 5, 191-196.	2.5	239
205	Haplotype analysis of common transthyretin mutations. Human Genetics, 1995, 96, 350-4.	3.8	21
206	Structural studies on FAP fibrils: removal of contaminants is essential for the interpretation of X-ray data. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1995, 2, 173-178.	3.0	13
207	TTR exon scanning in peripheral neuropathies. Neuromuscular Disorders, 1995, 5, 187-191.	0.6	18
208	TTR Leu 64 in an FAP kindred identified by PCR-RFLP analysis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1994, 1, 184-185.	3.0	1
209	Transthyretin ALA 71: A new transthyretin variant in a Spanish family with familial amyloidotic polyneuropathy. Human Mutation, 1993, 2, 420-421.	2.5	16
210	Retrovirus-mediated gene transfer of transthyretin and transthyretin-methionine 30: A potential tool for the study of amyloidogenesis. Neuromuscular Disorders, 1993, 3, 275-282.	0.6	2
211	Production of recombinant human transthyretin with biological activities toward the understanding of the molecular basis of familial amyloidotic polyneuropathy (FAP). Biochemistry, 1991, 30, 2415-2421.	2.5	86
212	Studies on the synthesis and secretion of transthyretin by the human hepatoma cell line Hep G2. FEBS Letters, 1991, 287, 193-196.	2.8	12
213	Recent advances in the molecular pathology of familial amyloid polyneuropathy. Neuromuscular Disorders, 1991, 1, 3-6.	0.6	28
214	Transthyretin Leu 68 in a form of cardiac amyloidosis. Basic Research in Cardiology, 1991, 86, 567-571.	5.9	39
215	Ocular changes in familial amyloidotic polyneuropathy with dense vitreous opacities. Eye, 1991, 5, 99-105.	2.1	14
216	A New Transthyretin Variant Associated with Familial Amyloidotic Polyneuropathy in an Italian Kindred. , 1991, , 599-602.		3

#	Article	IF	Citations
217	A TTR Acidic Variant DNA Analysis Of Homozygous and Heterozygous Individuals. , 1991, , 607-610.		0
218	Haplotype analysis of familial amyloidotic polyneuropathy. Human Genetics, 1989, 82, 9-13.	3.8	77
219	Tetramer formation of a variant type human transthyretin (prealbumin) produced byEscherichia coli expression system. Biochemical and Biophysical Research Communications, 1989, 163, 851-859.	2.1	17
220	Familial amyloidotic polyneuropathy: transthyretin (prealbumin) variants in kindreds of Italian origin. Human Genetics, 1988, 80, 341-343.	3.8	12
221	Onset in the seventh decade and lack of symptoms in heterozygotes for the TTRMet30 mutation in hereditary amyloid neuropathyâ€"type I (Portuguese, Andrade). American Journal of Medical Genetics Part A, 1987, 27, 345-357.	2.4	37
222	Family Studies of the Genetic Abnormality in Transthyretin (Prealbumin) in Portuguese Patients with Familial Amyloidotic Poly neuropathy. Annals of the New York Academy of Sciences, 1984, 435, 86-100.	3.8	50